- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Commencement of Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | 274 | GlobeNewswire (Europe) | New study to assess Halneuron pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing... ► Artikel lesen | |
| 15.05. | Dogwood Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Dogwood Therapeutics GAAP EPS of -$0.15 | 1 | Seeking Alpha | ||
| 14.05. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces First Quarter 2026 Financial Results | 1.096 | GlobeNewswire (Europe) | - Halneuron- Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy... ► Artikel lesen | |
| DOGWOOD THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.04. | Dogwood Therapeutics Announces FDA Acceptance Of IND Application For SP16 | 1 | RTTNews | ||
| 15.04. | Dogwood Therapeutics receives FDA clearance for SP16 pain trial | 2 | Investing.com | ||
| 15.04. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy | 202 | GlobeNewswire (Europe) | Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected... ► Artikel lesen | |
| 26.03. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Dogwood Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 18.03. | Virios Therapeutics GAAP EPS of -$0.26 | 1 | Seeking Alpha | ||
| 18.03. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | 386 | GlobeNewswire (Europe) | ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy... ► Artikel lesen | |
| 12.03. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.01. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.01. | Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron Through Phase 2b Development | 190 | GlobeNewswire (Europe) | Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics... ► Artikel lesen | |
| 08.01. | Dogwood Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 22.12.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain | 392 | GlobeNewswire (Europe) | - Halneuron- treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below... ► Artikel lesen | |
| 02.12.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Files New Synthetic Halneuron Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 | 315 | ACCESS Newswire | - New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron-- New Synthetic Process to be Used for Phase 3 Development Provides... ► Artikel lesen | |
| 11.11.25 | Dogwood Therapeutics, Inc.: Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 | 396 | ACCESS Newswire | - Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,85 | +0,25 % | Moderna prüft Kauf von Biontech-Werken in Deutschland | Berlin - Der US-Biotech-Konzern Moderna will in Deutschland in eigene Produktionsstandorte investieren. Interessant für die Pläne des Impfstoffherstellers sind die Werke, die der deutsche Konkurrent... ► Artikel lesen | |
| EVOTEC | 4,630 | +2,03 % | Vonovia blutet und kämpft, Evotec erneuert sich und dynaCERT expandiert, drei Aktien im Check! Wer hat die besseren Karten? | Drei Aktien, drei völlig unterschiedliche Storys und doch stehen alle drei gerade an einem Punkt, der über die nächsten Monate entscheiden dürfte. Vonovia z. B. kämpft gegen steigende Zinsen und einen... ► Artikel lesen | |
| VALNEVA | 2,300 | 0,00 % | EILMELDUNG bei Valneva: Hier baut sich gerade etwas Großes auf - Was erfahrene Anleger jetzt analysieren | ||
| AMGEN | 295,15 | +1,08 % | MariTide-Ausblick: Mizuho hebt Amgen-Kursziel auf 303 US-Dollar an | ||
| NOVAVAX | 8,000 | +0,63 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| BIOGEN | 170,64 | -0,23 % | Biogen Inc.: Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. | Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 developmentCAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen... ► Artikel lesen | |
| BIOFRONTERA | 2,280 | -3,80 % | BIOFRONTERA AG zeigt strukturelle Stärke | ||
| BIONXT SOLUTIONS | 0,220 | -1,35 % | Nurix, BioNxt Solutions, Zealand Pharma - Neue Therapien sorgen für Fantasie | Der Biotech-Sektor erlebt derzeit eine Phase enormer Dynamik. Besonders Therapien gegen Adipositas, Diabetes, Autoimmunerkrankungen und neurologische Leiden zählen zu den größten Wachstumsmärkten im... ► Artikel lesen | |
| CLINUVEL | 6,226 | -3,26 % | Why Clinuvel, Elevra Lithium, Regis Resources, and SCEE shares are racing higher today | ||
| VIKING THERAPEUTICS | 26,300 | -0,57 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer | Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval
SAN DIEGO, June 11, 2026 /PRNewswire/... ► Artikel lesen | |
| INFLARX | 1,540 | -2,16 % | WARNUNG für InflaRx NV-Anleger: Warum erfahrene Anleger zum Wochenstart die Reißleine ziehen - Was Monday-Trader jetzt wissen sollten | ||
| INTELLIA THERAPEUTICS | 13,520 | +1,20 % | Handel mit Optionen auf Intellia Therapeutics steigt sprunghaft an | ||
| TEMPUS AI | 43,635 | -0,05 % | Should You Retain Tempus AI Stock In Your Portfolio Now? | ||
| DEFENCE THERAPEUTICS | 0,307 | +0,33 % | Defence Therapeutics Inc.: Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions | Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| EDITAS MEDICINE | 2,380 | +1,71 % | Editas Medicine, Inc. - 8-K, Current Report |
Das Unternehmen DOGWOOD THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,550 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DOGWOOD THERAPEUTICS INC finden Sie auf Wallstreet Online.